These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27820607)

  • 1. Promotion of Drugs for Off-label Uses: The US Food and Drug Administration at a Crossroads.
    Kim J; Kapczynski A
    JAMA Intern Med; 2017 Feb; 177(2):157-158. PubMed ID: 27820607
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trial transparency--antidote to weaker off-label-promotion rules?
    Outterson K
    N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
    [No Abstract]   [Full Text] [Related]  

  • 3. After Amarin v FDA: What Will the Future Hold for Off-label Promotion Regulation?
    Mackey TK; Liang BA
    Mayo Clin Proc; 2016 Jun; 91(6):701-6. PubMed ID: 27084416
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulating off-label promotion of medications: has the pendulum swung too far?
    Hoffman MB; Yentzer BA; Feldman SR
    Skin Therapy Lett; 2015; 20(3):1-4. PubMed ID: 26382556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.
    Wang B; Studdert DM; Sarpatwari A; Franklin JM; Landon J; Kesselheim AS
    PLoS One; 2017; 12(4):e0175313. PubMed ID: 28388667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-label promotion: government theories of prosecution and facts that drive them.
    Burroughs AD; Levy MC; Schwab GG; Paik Y
    Food Drug Law J; 2010; 65(3):555-88. PubMed ID: 24479242
    [No Abstract]   [Full Text] [Related]  

  • 7. Pfizer settles largest ever fraud suit for off-label promotion.
    Ratner M
    Nat Biotechnol; 2009 Nov; 27(11):961-2. PubMed ID: 19898429
    [No Abstract]   [Full Text] [Related]  

  • 8. Off-label drug use and promotion: balancing public health goals and commercial speech.
    Kesselheim AS
    Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880
    [No Abstract]   [Full Text] [Related]  

  • 9. United States v. Caronia: Off-Label Drug Promotion and First Amendment Balancing.
    Rabinowitz DP
    Fordham Law Rev; 2018 Apr; 86(5):2595-623. PubMed ID: 29993225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Origins of the prohibition against off-label promotion.
    Coleman TS
    Food Drug Law J; 2014; 69(2):161-236, i. PubMed ID: 25163210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Snake oil salesmen or purveyors of knowledge: off-label promotions and the commercial speech doctrine.
    Bagley CE; Mitts J; Tinsley RJ
    Cornell J Law Public Policy; 2013; 23(2):337-93. PubMed ID: 25330567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forbidden and Permitted Statements about Medications--Loosening the Rules.
    Avorn J; Sarpatwari A; Kesselheim AS
    N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
    [No Abstract]   [Full Text] [Related]  

  • 13. Investigating pharmaceutical marketing in Canada using American prosecutions.
    Shoucri R; Persaud N
    Int J Risk Saf Med; 2014; 26(3):147-53. PubMed ID: 25214160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Criminalizing knowledge: the perverse implications of the intended use regulations of off-label promotion prosecutions.
    Gentry G
    Food Drug Law J; 2009; 64(3):441-58. PubMed ID: 19999637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-label marketing: free speech or illegal promotion?
    Silverman E
    BMJ; 2013 Jan; 346():f320. PubMed ID: 23341546
    [No Abstract]   [Full Text] [Related]  

  • 16. 'The First Amendment and off-label promotion: why the court in United States v. Caronia, got it wrong.
    Ball FR; Duffy EM; Russakoff NL
    Health Care Law Mon; 2009 Apr; 2009(4):2-11. PubMed ID: 19374328
    [No Abstract]   [Full Text] [Related]  

  • 17. Enforcement related to off-label marketing and use of drugs and devices: where have we been and where are we going?
    Joseph JN; Deaton D; Ehsan H; Bonanno MA
    J Health Life Sci Law; 2009 Jan; 2(2):73-108. PubMed ID: 19288889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulating Off-Label Promotion - A Critical Test.
    Robertson C; Kesselheim AS
    N Engl J Med; 2016 Dec; 375(24):2313-2315. PubMed ID: 27805841
    [No Abstract]   [Full Text] [Related]  

  • 19. The next forum for unraveling FDA off-label marketing rules: State and federal legislatures.
    Sinha MS; Kesselheim AS
    PLoS Med; 2018 May; 15(5):e1002564. PubMed ID: 29738523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.